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Abstract
Background: Barth Syndrome (BTHS) is a serious X-linked genetic disorder associated with mutations in the tafazzin
gene (TAZ, also called G4.5). The multi-system disorder is primarily characterized by the following pathologies:
cardiac and skeletal myopathies, neutropenia, growth delay, and exercise intolerance. Although growth anomalies
have been widely reported in BTHS, there is a paucity of research on the role of inflammation and the potential link
to alterations in growth factors levels in BTHS patients.
Methods: Plasma from 36 subjects, 22 patients with Barth Syndrome (0.5 - 24 yrs) and 14 healthy control males
(8 - 21 yrs) was analyzed for two growth factors: IGF-1 (bound and free) and Growth Hormone (GH); and two
inflammatory cytokines IL-6 and TNF-α using high-sensitivity enzyme-linked immunosorbent assays.
Results: The average IL-6 and IL6:IGF ratio levels were significantly higher in the BTHS (p = 0.046 and 0.02
respectively). As for GH, there was a significant group by age interaction (p = 0.01), such that GH was lower for BTHS
patients under the age of 14.4 years and higher than controls after age 14.4 years. TNF-α levels were not
significantly different, however, the TNF-α:GH was lower in BTHS patients than controls (p = 0.01).
Conclusions: Comparison of two anabolic growth mediators, IGF and GH, and two catabolic cytokines, IL-6 and
TNF-α, in BTHS patients and healthy age-matched controls demonstrated a potential imbalance in inflammatory
cytokines and anabolic growth factors. Higher rates of IL-6 (all ages) and lower GH levels were observed in BTHS
patients (under age 14.5) compared to controls. These findings may implicate inflammatory processes in the
catabolic nature of Barth Syndrome pathology as well as provide a link to mitochondrial function. Furthermore,
interactions between growth factors, testosterone and inflammatory mediators may explain some of the variability
in cardiac and skeletal myopathies seen in Barth Syndrome.
Keywords: Myopathy, dilated-cardiac myopathy, inflammation, catabolic, cardiolipin, mitochondria
Background
Barth Syndrome (BTHS) is a serious X-linked genetic dis-
order associated with mutations in the tafazzin gene (TAZ,
also called G4.5). This multi-system disorder is primarily
characterized by the following pathologies: cardiomyopathy
(dilated or hypertrophic), neutropenia (chronic, cyclic, or
intermittent), hypotonia and muscle weakness, growth
delay, exercise intolerance, cardiolipin abnormalities, and
3-methylglutaconic aciduria. Barth Syndrome is believed to
be severely under-diagnosed and is estimated to occur in
one out of approximately 300,000 births[1]. Being able to
analyze plasma from 22 BTHS patients against health con-
trol subjects in such a rare disease population is note-
worthy strength of this study.
Although growth anomalies have been widely reported
in BTHS, there is a paucity of research on the contribution
of catabolic/anabolic processes, the influence of inflamma-
tion and the potential link to alterations in growth factor
levels in BTHS patients. Recently, however there has been
growing evidence that inflammatory processes may influ-
ence normal muscle development in children. Increased
levels of Tumor Necrosis Factor alpha (TNF-α) have been
shown to suppress the AKT/mTOR (mammalian target of
rapamyosin) pathway, a crucial pathway for regulating
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skeletal muscle hypertrophy and thereby increase muscle ca-
tabolism [2-4]. Inflammatory cytokines may also antagonize
the anabolic effects of Insulin-like growth factor (IGF), a
known promoter of muscle hypertrophy [5-7]. Normal levels
of physical activity have been linked to a balance between
anabolic factors such as IGF-1 and Growth Hormone (GH)
and catabolic cytokines such as Interleukin-6 (IL-6) and
TNF-α. For example, higher levels of IL-6 and lower levels
of IGF-1 have also been observed in children with chronic
inflammatory diseases such as juvenile idiopathic arthritis,
inflammatory bowel disease and cystic fibrosis [8,9]. Thus it
is plausible that a catabolic/anabolic imbalance, linked to an
inflammatory process, contributes to the growth abnormal-
ities and pathology observed in BTHS.
We hypothesized that patients diagnosed with BTHS
would have an imbalance in catabolic and anabolic media-
tors such that BTHS would have lower levels of growth
factors and higher levels of inflammatory mediators com-
pared to age-matched healthy controls. This study
addresses this question by statistical analysis of IGF-1, GH,
IL-6 and TNF-α plasma levels obtained from BTHS
patients and healthy controls.
Methods
Sample characteristics
The sample population for this study included 36 subjects,
22 BTHS patients (age 4 months to 24 yrs) and 14 healthy
controls (age 8 to 21 years). Plasma and clinical informa-
tion from the BTHS patients was provided by the Barth
Syndrome Foundation Bioregistry. Plasma from healthy
controls was obtained from subjects participating in stud-
ies conducted through the Pediatric Department at the
University of California, Irvine (UCI). All subjects were
knowing and willing plasma donors as members of Barth
Syndrome Foundation or from IRB-approved studies at
UCI. The UCI studies involved children age eight years
and older, therefore plasma samples were not available
from for healthy controls below age eight. Exclusion cri-
teria for healthy controls included having had an upper re-
spiratory infection or inflammatory illness such as asthma.
Furthermore, healthy controls subjects had not utilized any
antibiotics or non-steroidal anti-inflammatory (NSAID)
medications prior to the study (14-days for antibiotics and
7-days for NSAIDs).
Blood acquisition, processing and cytokine measurement
Plasma from both the BTHS patients and healthy controls
was obtained via standard phlebotomy procedures. Within
two hours of acquisition, blood was centrifuged and stored
at −80 °C. Barth Syndrome samples were shipped on dry
ice and immediately stored at −80 °C so that they would be
thawed only once for analysis.
Cytokines and growth mediators were measured using
high-sensitivity Immunoassay quantification kits, as fol-
lows: IL-6 and TNF-α were measured using kits by R&D
Technologies, IGF-1 (bound and free) was measured using
a DSL kit, and human Growth Hormone was measured
using the RayBiomed kit. The sensitivity of the tests were:
IL-6 (0.016 pg/mL), TNF-α (0.038 pg/mL), IGF-1
(0.015 ng/mL) and GH (4.0 pg/mL). All samples were run
on a single 96- well plate. Duplicates were run for ran-
domly selected BTHS patients and healthy controls to fill
all wells of the single plate.
Statistical analysis
We implemented linear regression modeling to find the sets
of significant predictors for all outcomes variables of inter-
est and quantify the corresponding effect sizes. All study
variables were considered in the model building process as
potential independent predictors or confounders with main
covariates of interest being age, case–control status (BTHS
versus Healthy Controls), and their interaction. Thus, separ-
ate best predictive models were derived and assessed for
goodness of fit for IL-6, IGF1-β, GH, absolute neutrophil
count, as well as the ratios between IL-6 and IGF-1 (IL6:
IGF), and TNF and GH (TNF:GH). For models in which
age revealed a nonlinear effect on the outcome variable, a
discretized version of age (puberty) was used with interval
allocation, 0–7, 8–11, 12–16, and 18–21 years of age.
Table 1 Demographic Data on Study Sample Population
Age Group (years)
Healthy Controls by Age Group (mean± SD (n)) BTHS by Age Group (mean± SD (n))
Variable 0.5 to 7 8 to 11 12 to 16 18 to 21 0.5 to 7 8 to 11 12 to 16 18 to 24
Age (yrs) ~ 9.1 ± 0.9(5) 14.2 ± 1.5(5) 19.7 ± 1.5(4) 3.2 ± 2.3(7) 9.3 ± 1.3(4) 14.0 ± 1.8(4) 20.9 ± 2.2(7)
Height (cm) ~ 130.9 ± 4.7(5) 172.1 ± 11.7(5) 179.2 ± 13.5(4) ~ 23.9 ± 0.9(2) 162.3 ± 9.8(3) 177.0 ± 7.8(5)
Weight (kg) ~ 28.1 ± 3.1(5) 69.7 ± 19.7(5) 75.2 ± 5.1(4) ~ 21.9 ± 1.1(2)* 45.6 ± 3.1(3)* 56.6 ± 15.4(5)*
* Indicates statistically significant difference in weight (p< 0.001).
~ Indicates missing data.
Table 2 Model Summary of the Significant Predictors
of IL-6
Variable Estimate Standard Error t-value p-value
Intercept 0.81 0.93 0.87 0.39
Group (BTHS vs. Control) 2.38 1.18 2.01 0.046
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All computational steps were carried out using the R
statistical software language (R Development Core Team
(2008) [10].
Results
Demographic characteristics
Demographic data are presented in Table 1. As stated pre-
viously, matched controls were not available under the age
of eight years. Height and weight data were missing for the
following five BTHS patients: two age 8–11 years, one age
12–16 years, and two age 18 to 24 years. Age and height
did not differ significantly between controls and BTHS
patients within the age groups; however, the BTHS patients
had significantly lower body weight than healthy controls
(p< 0.001).
Catabolic and anabolic mediator levels
There was no effect of age on IL-6 (both linear and non-
linear trends were considered and tested) and the only
significant predictor was BTHS status (details given in
Table 2). Our results show that on average, the BTHS
group possessed significantly higher IL-6 levels (p= 0.046)
throughout their lives compared to the healthy controls
with mean IL-6 values of 3.19 and 0.81 pg/mL respectively.
Graphical comparison of the two distributions is presented
in Figure 1. The R2 value for this model was 0.13 reflecting
the inherent variability in the IL-6 measurements.
With respect to IGF-1, the mean IGF-1 levels for the
Controls and BTHS Patients were 286.39 and 197.90 ng/mL
respectively (p=0.05). This difference was found to be
spurious, however, with linear regression since it was driven
by the underlying contribution of differences in the distribu-
tions of age and height between the two groups. This is evi-
denced by the fact that after adjustment for height and age,
the case–control status becomes highly non-significant
(p=0.46). We found that height, age, and the height * age
interaction were significant predictors of IGF-1 levels. After
controlling for these factors, having BTHS no longer played
a significant role in the prediction of IGF-1 (details given in
Table 3). The presence of the interaction term between two
continuous variables makes the relationship between IGF-1
and height and age difficult to interpret. However, the nega-
tive sign of interaction accounts for the decrease of the IGF-
1 levels after age 17 (scatterplots of both the height and age
variables versus IGF-1 are presented in Figure 2. The R2
value for this model was 0.79 indicating a high level
goodness-of-fit.
With respect to GH, we found that the significant pre-
dictors were BTHS status, age and their interaction (details
given in Table 4). The presence of the interaction term be-
tween the continuous variable age and factor variable de-
noting Barth Syndrome status defines a model that
incorporates different slopes and different intercepts for
the BTHS and Control group (scatterplot and regression
lines are presented in Figure 3). The BTHS patients have
lower GH levels compared to healthy controls for ages
younger than 14.4 years and higher GH levels for ages
older than 14.4 years. As GH is known to be secreted in
several pulses or peaks during the day, with wide variations
between days and individuals, these naturally occurring
Controls Barth Syndrome
0
1
2
3
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IL
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Figure 1 IL-6 in Barth Syndrome Patients and Healthy Controls. Box Plot distribution of circulating IL-6 levels in Controls and BTHS patients.
IL-6 levels were significantly higher across all age groups, (p = 0.046).
Table 3 Model Summary of the Significant Predictors
of IGF-1
Variable Estimate Standard Error t-value p-value
Intercept −1379.60 382.32 −3.61 0.002
Height (cm) 11.71 2.48 4.71 <0.001
Age (years) 56.02 31.37 1.79 0.09
Height * Age −0.42 0.19 −2.27 0.03
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fluctuations can introduce variability, which was reflected
in the R2 value of 0.19 for this model.
With respect to IL-6:IGF-1 ratio, we found that there
was no effect of age (both linear and nonlinear trends were
considered and tested) and the only significant predictor
was BTHS status (details given in Table 5). Our results
show that on average, Barth Syndrome patients possessed
significantly higher IL-6:GF-1 ratios (p =0.03) throughout
the age groups analyzed compared to the healthy controls
with mean.
IL-6:IGF-1 ratios of 0.003 and 0.034 respectively. Graph-
ical comparison of the two distributions is presented in
Figure 4. The R2 value for this model was 0.13 reflecting
the inherent variability in the IGF-1 measurements
induced by IL-6.
Lastly, with respect to TNF:GH ratio, we found that
there was no effect of age (both linear and nonlinear trends
were considered and tested) and the only significant pre-
dictor was Barth Syndrome status (details given in Table 6).
Our results show that on average, the Barth Syndrome
group possessed significantly lower (p=0.02) TNF:GH
ratios throughout their lives compared to the healthy con-
trols with mean TNF:GH ratios of 0.004 and 0.019 respect-
ively. Graphical comparison of the two distributions is
presented in Figure 5. The R2 value for this model was 0.17
reflecting the inherent variability of the TNF:GH ratio
induced by both TNF and GH values.
Discussion
Lower levels of two anabolic growth mediators, (IGF and
GH), and a higher level of the catabolic cytokine IL-6 were
observed in this study and point to an imbalance which
could contribute to some of the myopathies and growth
delays present in BTHS patients. Higher levels of IL-6 have
been found in sedentary children and adolescents as well
as in chronic diseases of childhood [11,12]. Indeed, the
levels of IL-6 observed in this group of BTHS patients were
similar to those reported in children with Type I diabetes
mellitus [13], suggesting the contribution of a low-grade
inflammatory process. Thus two potential explanations for
the higher IL-6 levels in Barth Syndrome include the lower
levels of physical activity resulting from exercise intoler-
ance and low grade inflammatory processes in Barth Syn-
drome. This study demonstrates, for the first time, a
catabolic/anabolic imbalance, with a link to chronic inflam-
mation, in BTHS patients which may explain the growth
abnormalities and myopathies associated with this
syndrome.
The present case is a complex and sophisticated example
of the importance of implementing regression modeling in
the statistical analysis of IGF-1. While it appeared as if
IGF-1 was lower in the BTHS patients (mean IGF-1 for
Controls = 286.4 ng/mL and BTHS 197.90 ng/mL respect-
ively, p = 0.05). This difference was found to be spurious
with linear regression since it was driven by the underlying
contribution of differences in the distributions of age and
height between the two groups. After adjusting for height
Figure 2 Predictors of IGF-1. Both Age (Figure to Left) and Height (Figure to Right) were correlated with IGF-1 level. Changes across Age and
Height did not differ between BTHS (open circles) and Controls (closed boxes).
Table 4 Model Summary of the Significant Predictors of
GH
Variable Estimate Standard Error t-value p-value
Intercept 11602.30 3313.10 3.50 0.001
Group (BTHS vs. Control) −9216.00 3598.20 −2.56 0.02
Age (years) −624.30 236.20 −2.64 0.01
Group * Age 639.90 256.60 2.49 0.01
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and age, the case–control status was found not be signifi-
cant (p= 0.46). This is a clear example in which regression
modeling detects the true predictors of IGF-1 levels while
direct approaches such as correlation analysis would have
been inaccurate. The authors suggest that further investi-
gation of IGF-1 be conducted and that study subjects be
age and height matched so that the exact contribution of
case control status can be identified.
Growth delays are widely recognized in BTHS with
accelerated to normal growth occurring during the mid- to
late- teenage years. IGF is well known to be closely corre-
lated with growth in adolescents [14]. Moreover, numerous
studies demonstrate that IGF levels predict both height
and weight [15,16]. We also found this to be true for both
the BTHS patients as well as the healthy controls. In the
BTHS patients, IGF was highly correlated with both height
and weight (bivariate correlations, R2 = 0.77 for height and
R2 = 0.71 for weight). Thus, IGF signaling for bone growth
appeared to be “normal” in the BTHS patients. This was
despite significant differences in weight; (lower weights in
BTHS). We hypothesize that the lower weights were due
to reduce muscle development and not bone growth in the
BTHS patients. A possible explanation for the reduced
muscle mass in BTHS patients is differences in the medi-
ator milieu of the muscle during early development. This is
supported by studies demonstrating that cell signaling in
the muscle is influenced by the mediator environment.
Adams and colleagues showed differences in cell signaling
in the muscle of rats based upon either acute or chronic
exposure to IL-6 [17]. Chronic IL-6 exposure reduced
muscle growth whereas acute exposure occurring with
regular exercise training enhanced muscle growth. Indeed,
differences in mediators during early development may
also account for the delay in bone growth observed in
BTHS patients.
The achievement of normal height in adolescent BTHS
patients is an intriguing occurrence and a phenomenon
that is not unknown in pediatrics. It is well recognized that
children suffering from malnutrition or with health pro-
blems causing poor growth have “catch-up growth.”
Catch-up growth is a growth spurt that occurs when nor-
mal conditions are restored. Recently, IGF has been shown
to be involved in catch-up growth [18]. In a study of zebra-
fish, in which growth delays occurred from oxygen
deprivation but catch-up growth occurred following restor-
ation of oxygen, it was demonstrated that catch-up growth
could be blocked by blocking IGF. The specific pathway
involved is the IGF-MAP kinase pathway; however, it may
not be the only pathway that figures in, and the specific
pathway used may depend on circumstances.
Additionally, other mechanisms may be are implicated in
catch-up growth in BTHS patients. For example, we found
that GH levels increased after the age of 14.4 years in
BTHS and another potential explanation is the coinciden-
tal pubertal-related increase in testosterone. Testosterone
is known to increase the effectiveness of IGF signaling via
improvement in binding protein interactions (i.e. IGF BP 4
and 5)[14]. This has the potential to synergistically impact
GH expression and activation because cells which were
previously resistant to IGF or GH may become more sensi-
tive to increases via binding proteins. This may be from
Figure 3 Changes in GH by Group over Time. Scatter plot of circulating GH level by Age for BTHS (open circles) and Controls (closed boxes).
Interaction can be seen at the point in which the slope of the BTHS patients (dashed line) crosses the Controls (solid line). BTHS patients had
significantly lower GH levels before the age 14.5 years.
Table 5 Model Summary of the Significant Predictors of
IL-6:IGF-1
Variable Estimate Standard Error t-value p-value
Intercept 0.003 0.011 0.31 0.76
Group (BTHS vs. Control) 0.031 0.014 2.22 0.03
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testosterone, IL-6 or from completely unidentified
mechanisms. For example, infusion of IL-6 has also been
shown to increase IGF sensitivity in acute scenarios [17].
Most recently, convergent mechanism for both cytokines
and growth factors in cell signaling in skeletal muscle have
been elucidated [18]. Transcription factors have been iden-
tified that demonstrate overlap between IL-6 and IGF in
the cell replication cycle include: Janus kinase/signal trans-
ducer activator of transcription (JAK/STAT) pathway and
suppressors of cytokine signaling (SOCS). Weigert et al.
found that acute treatment with IL-6 failed to stimulate
increases in SOC3 expression; however, Adams et al. found
that long-term exposure elevated levels of SOCS3 mRNA
[17,19]. Thus, several factors may be involved in the
growth delay seen in BTHS and subsequent catch-up
growth.
The influence of IL-6 on growth may involve a paradox-
ical effect. Indeed, the role of IL-6 in muscle has been
shown to demonstrate an intriguing paradox [20]. Exercis-
ing muscle is known to increase IL-6 production; while at
the same time elevated IL-6 expression is often found dur-
ing muscle wasting conditions [21]. In the BTHS patients,
circulating IL-6 levels were significantly higher across all
age groups (neither age nor pubertal status were signifi-
cant). Since BTHS patients are exercise intolerant, there
are two possibilities: 1) that normal daily activities in the
BTHS patients mimic intense exercise in the muscles of
healthy controls, i.e. normal activity increases circulating
IL-6 in Barth Syndrome, or 2) that IL-6 is being secreted at
higher levels by immune cells (possibly dysfunctional neu-
trophils) in Barth Syndrome patients relative to healthy
controls. These hypotheses offer two valuable areas of re-
search in the area of IL-6 production by muscle and/or im-
mune cell.
Most recently, convergent mechanism for both cytokines
and growth factors in cell signaling in skeletal muscle have
been elucidated [21]. Transcription factors have been iden-
tified that demonstrate overlap between IL-6 and IGF in
the cell replication cycle include: Janus kinase/signal trans-
ducer activator of transcription (JAK/STAT) pathway and
suppressors of cytokine signaling (SOCS). Weigert et al.
found that acute treatment with IL-6 failed to stimulate
increases in SOC3 expression; however, Adams et al. found
that long-term exposure elevated levels of SOCS3 mRNA.
Duan and colleagues also demonstrated that altering IGF
in muscles alters growth [22]. In this study, age was signifi-
cantly correlated with IGF-1 but not GH (r=−0.16,
p= 0.36). It is possible that the delayed peak in GH is con-
tributory to the growth delays observed in Barth Syn-
drome. Moreover, there is growing evidence linking GH
levels with mitochondrial damage [23,24]. It has been pro-
posed that lower levels of circulating GH may limit mito-
chondrial uptake of GH and contribute to the
mitochondrial damage such as is associated with Barth
Syndrome. It has been shown that extracellular supplies of
GH are taken up and localize to the mitochondria [23,24].
These findings provide a potential link between reduced
growth mediator levels and mitochondrial dysfunction.
The IGF "axis" is also commonly referred to as the
Growth Hormone/IGF1 Axis. IGF-1 is mainly secreted by
the liver as a result of stimulation by GH. The diurnal vari-
ation of GH is well documented. For this reason, IGF and
its binding proteins are often measured simultaneously to
Controls Barth Syndrome
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Figure 4 IL-6:GF-1 Ratio in BTHS and Controls. Box plot distribution of IL-6:IGF-1 ratio BTHS patients and Controls. The IL-6:IGF-1 ratio was
significantly higher in BTHS patents across all age groups (p = 0.03).
Table 6 Model Summary of the Significant Predictors of
TNF:GH
Variable Estimate Standard Error t-value p-value
Intercept 0.019 0.004 3.93 <0.001
Group (BTHS vs. Control) −0.015 0.006 −2.52 0.02
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assess growth delays and gigantisms because they are
stable over time [25].
One of the most interesting findings of this study
involved the link between IL-6 and IGF-1, specifically the
significantly higher IL-6:IGF-1 ratio in BTHS patients.
There is increasing evidence that inflammation contributes
to the necrosis of dystrophic myofibers in Duchenne mus-
cular dystrophy[7]. IGF plays a central role in myofibril
hypertrophy and atrophy and this balance is of critical im-
portance in sarcopenia, cachexia, and metabolic syndrome
[26,27]. The combination of both a slight increase in IL-6
and small decrease in IGF-1 may have a more substantial
contribution to muscle and cardiac myopathies than previ-
ously considered in BTHS.
Contrary to the higher IL-6:IGF ratio in BTHS, the TNF-
α:GH ratio was significantly lower in Barth patients than
controls in the older age groups. A study controlling for di-
urnal variation in GH would be important to understand
the clinical implications of this finding, in particular be-
cause there were not differences in TNF-α by comparison
group. In regards to the TNF-α:IGF ratio, age was a highly
significant predictor of the differences in this catabolic:ana-
bolic ratio outcome (p=0.004) in this study. After control-
ling for age, however, the group effect (BTHS vs. control)
was not significant (p= 0.236). The relationship to these
two factors remains of interest since it has been shown that
IGF-1 was preventative of and TNF-α enhanced myocar-
dial injury after ischemia/reperfusion following myocardial
infarction [28].
A limitation of this study includes the lack of full control
and potential variation in the time of day plasma collection
from BTHS patients. Also the amount of time between ac-
quisition and storage may have differed within the sample.
Sack and colleagues found that plasma concentrations of
TNF-α were remarkably unstable and that it should be
measured immediately post blood draw [29]. Sacks also
found that TNF levels were highly variable during child-
hood and should be analyzed with great precaution.
Another weakness is the small sample size and cross-
sectional nature of the study. We believe, further investiga-
tion into the role of TNF-α in Barth Syndrome cardiac and
skeletal myopathies is warranted in a larger and more well-
characterized group.
Conclusion
Comparison of two anabolic growth mediators, IGF and
GH, and two catabolic cytokines, IL-6 and TNF-α, in Barth
Syndrome patients and healthy age-matched controls
demonstrated a possible catabolic:anabolic imbalance in
Barth Syndrome. Higher rates of IL-6 and lower IGF-1
levels were observed in BTHS compared to controls. This
finding may implicate inflammatory processes in the cata-
bolic nature of Barth Syndrome pathology as well as pro-
vide a link to mitochondrial dysfunction. Furthermore,
lower levels of IGF-1 may contribute to some of the
growth delays and myopathies observed in Barth
Syndrome.
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